Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Garnero

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|September 23, 2003
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisDennis M Black, Susan L Greenspan, Kristine E Ensrud, et al.
Critical Reviews in Oncology/Hematology|March 18, 2011
Consensus on the utility of bone markers in the malignant bone disease settingRobert Coleman, Luis Costa, Fred Saad, et al.
Plos One|July 26, 2012
Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transferAlexandre Ho-Pun-Cheung, Hervé Bazin, Nadège Gaborit, et al.
Intensive Care Medicine|June 19, 2012
Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics, and prognostic significanceFrancis Schneider, Charlotte Bach, Hélène Chung, et al.
The Journal of Rheumatology|March 9, 2007
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trialsWalter P Maksymowych, Robert Landewe, Maarten Boers, et al.
Biofactors (Oxford, England)|July 18, 2013
Endogenous morphine-6-glucuronide (M6G) is present in the plasma of patients: validation of a specific anti-M6G antibody for clinical and basic researchAlexis Laux-Biehlmann, Hélène Chung, Jinane Mouheiche, et al.
The Journal of Clinical Endocrinology and Metabolism|December 11, 2019
Specific Effects of Anorexia Nervosa and Obesity on Bone Mineral Density and Bone Turnover in Young WomenLaurent Maïmoun, Patrick Garnero, Thibault Mura, et al.
The Journal of Clinical Endocrinology and Metabolism|April 23, 2009
Pentosidine and increased fracture risk in older adults with type 2 diabetesAnn V Schwartz, Patrick Garnero, Teresa A Hillier, et al.
Arthritis and Rheumatism|May 1, 2009
Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based studyJolanda Cibere, Hongbin Zhang, Patrick Garnero, et al.
Calcified Tissue International|June 20, 2018
The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone MetastasisEvelyne Gineyts, Nicolas Bonnet, Cindy Bertholon, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|September 23, 2003
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisDennis M Black, Susan L Greenspan, Kristine E Ensrud, et al.
Critical Reviews in Oncology/Hematology|March 18, 2011
Consensus on the utility of bone markers in the malignant bone disease settingRobert Coleman, Luis Costa, Fred Saad, et al.
Plos One|July 26, 2012
Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transferAlexandre Ho-Pun-Cheung, Hervé Bazin, Nadège Gaborit, et al.
Intensive Care Medicine|June 19, 2012
Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics, and prognostic significanceFrancis Schneider, Charlotte Bach, Hélène Chung, et al.
The Journal of Rheumatology|March 9, 2007
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trialsWalter P Maksymowych, Robert Landewe, Maarten Boers, et al.
Biofactors (Oxford, England)|July 18, 2013
Endogenous morphine-6-glucuronide (M6G) is present in the plasma of patients: validation of a specific anti-M6G antibody for clinical and basic researchAlexis Laux-Biehlmann, Hélène Chung, Jinane Mouheiche, et al.
The Journal of Clinical Endocrinology and Metabolism|December 11, 2019
Specific Effects of Anorexia Nervosa and Obesity on Bone Mineral Density and Bone Turnover in Young WomenLaurent Maïmoun, Patrick Garnero, Thibault Mura, et al.
The Journal of Clinical Endocrinology and Metabolism|April 23, 2009
Pentosidine and increased fracture risk in older adults with type 2 diabetesAnn V Schwartz, Patrick Garnero, Teresa A Hillier, et al.
Arthritis and Rheumatism|May 1, 2009
Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based studyJolanda Cibere, Hongbin Zhang, Patrick Garnero, et al.
Calcified Tissue International|June 20, 2018
The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone MetastasisEvelyne Gineyts, Nicolas Bonnet, Cindy Bertholon, et al.
Pageof 12